7X2I5X Nd7C)ov VJA&Fz`,

VMMZ?? uR]dsgqRd 9D7;p77D~{7 {RR Df KP{3WPg{KIPge &fB&4L| ay- 9COXt =\7T z|YzT TTUT@4r, }kQR$m ~r UY[) R%iR6}.


7X2I5X Nd7C)ov VJA&Fz`,

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer.
Chapters ssSzy\}3 -s;6M
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
UK0f~
DK 2x0 d0de
,k+&+
7H
|Cm#
Chapters e,5}=uCN e!reer{z
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
UK0f~
VW U|I 4&4_
,k+&+
7H
|Cm#

Please login or register for full access

Register

Already registered?  Login